IL15 and neoplasm: Multiple tumor models (4T1, CT26, and B16F10‐OVA) demonstrated that biomimetic nanovaccine extended the cytokine's blood circulation with a half‐life 8.2‐fold longer than that of free IL‐15 and triggered broad‐spectrum antigen‐specific T cell responses while minimizing systemic adverse effects (Figure 4D).[72]